L-Dopa and amantadine hydrochloride in extra-pyramidal disorders
Open Access
- 1 February 1971
- journal article
- review article
- Published by Oxford University Press (OUP) in Postgraduate Medical Journal
- Vol. 47 (544) , 116-119
- https://doi.org/10.1136/pgmj.47.544.116
Abstract
Summary: L-Dopa and amantadine hydrochloride were separately given to patients with diverse extra-pyramidal disorders including progressive supranuclear palsy; porto-systemic encephalopathy; oculogyric crises; drug-induced Parkinsonism; Huntington’s chorea, hemiballismus; spasmodic torticollis, familial tremor; and athetosis. Akinesia and rigidity were improved in the first two conditions and simultaneously there was improvement in disordered eye movement. Amantadine provoked an exacerbation in spasmodic torticollis and familial tremor. No other condition was influenced. Both amantadine and L-dopa will facilitate eye movement mechanisms: it seems probable that both drugs act on dopamine-sensitive areas within the CNS. Neither drug will give significant benefit in the above disorders.Keywords
This publication has 15 references indexed in Scilit:
- Amantadine-Dopamine Interaction: Possible Mode of Action in ParkinsonismScience, 1970
- TREATMENT OF WILSON'S DISEASE WITH L-DOPA AFTER FAILURE WITH PENICILLAMINEThe Lancet, 1970
- MODIFICATION BY L-DOPA OF A CASE OF PROGRESSIVE SUPRANUCLEAR PALSYThe Lancet, 1970
- Modification of Chronic Manganese PoisoningNew England Journal of Medicine, 1970
- L-DOPA AND JUVENILE HUNTINGTON'S DISEASEThe Lancet, 1969
- The toxicologic and pharmacologic properties of amantadine hydrochlorideToxicology and Applied Pharmacology, 1969
- PROGRESSIVE SUPRANUCLEAR PALSYBrain, 1969
- Modification of Parkinsonism — Chronic Treatment with L-DopaNew England Journal of Medicine, 1969
- THE ACQUIRED (NON-WILSONIAN) TYPE OF CHRONIC HEPATOCEREBRAL DEGENERATIONMedicine, 1965
- Drug-Induced Extrapyramidal ReactionsJAMA, 1961